Active ingredientCeftobiproleCat. No. P-C106-001CAS 209467-52-7Family · Pharmaceutical analytical standards
Ceftobiprole
An intravenous fifth-generation cephalosporin, active even against methicillin-resistant Staphylococcus aureus (MRSA): approved in Canada and several European countries for pneumonia and, in 2024, in the United States as well. This family brings together the active ingredient and other impurities.
Did you know?Its trump card is PBP2a, the protein MRSA uses to escape other beta-lactams: ceftobiprole binds it with high affinity. It is given as a prodrug, ceftobiprole medocaril.
Go to the active ingredient →Active ingredientCeftobiproleCat. No. P-C106-001CAS 209467-52-7
ImpurityCeftobiprole MedocarilCat. No. P-C106-003CAS 376653-43-9
ImpurityCeftobiprole medocaril sodiumCat. No. P-C106-004CAS 252188-71-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.